For many years, low-density lipoprotein (LDL) cholesterol, commonly referred to as “bad cholesterol,” has served as a key indicator for evaluating an individual’s risk of developing heart disease. Nevertheless, a recent investigation featured in JAMA indicates that a different blood test known as apolipoprotein B (apoB) may more effectively pinpoint those genuinely at risk of experiencing heart attacks and strokes.
According to researchers, apoB assesses the quantity of harmful cholesterol-carrying particles present in the bloodstream instead of merely measuring the cholesterol they contain. This implies that individuals with normal LDL cholesterol levels might still possess a high concentration of atherogenic particles that can harm arteries, thereby increasing their risk for cardiovascular issues.
The study raised the question, “In primary prevention, would utilizing an apolipoprotein B (apoB) target to guide the intensification of lipid-lowering therapy (LLT) be more cost-effective than relying on low-density lipoprotein cholesterol (LDL-C) or non–high-density lipoprotein cholesterol (non–HDL-C) goals?”
Dr. K K Talwar, Chairman of the PSRI Heart Institute, notes that this study contributes to the accumulating evidence that apoB is a more reliable measure of cardiovascular risk compared to LDL cholesterol alone.
“These findings are significant as they reinforce the notion that ApoB serves as a superior marker for cardiovascular risk than LDL cholesterol by itself. While LDL cholesterol quantifies the cholesterol contained within LDL particles, ApoB evaluates the actual number of atherogenic lipoprotein particles capable of penetrating arterial walls and inducing plaque formation. Each of these detrimental particles is associated with one apoB molecule, indicating that apoB directly counts the particles that can lead to atherosclerosis,” explains Dr. Talwar.
He further remarks that, although the results are encouraging, the routine adoption of apoB testing will hinge on forthcoming evidence. “If future research validates enhanced patient outcomes and cost-effectiveness, apoB testing could gain traction in clinical settings. Currently, apoB is recognized as a valuable risk assessment tool in various international guidelines, particularly for select high-risk groups. However, additional real-world data regarding its implementation and costs across different demographics will be necessary before it can replace standard lipid testing.”
Dr. Talwar highlights that apoB testing is especially beneficial for individuals whose cardiovascular risk may not be fully captured by traditional lipid profiles. “ApoB testing proves particularly valuable for people whose risk of heart disease might be overlooked by conventional lipid assessments. This includes individuals with diabetes, obesity, metabolic syndrome, elevated triglycerides, chronic kidney disease, a significant family history of premature heart disease, or those who have previously experienced a cardiovascular event.”
He clarifies that in these cases, LDL cholesterol levels may appear normal, despite a high number of harmful lipoprotein particles being present. “ApoB testing can uncover this hidden risk, facilitating more tailored treatment decisions.” However, he stresses that apoB is not intended to replace the standard lipid profile.
“A routine lipid profile remains an effective initial screening tool for the general population with low cardiovascular risk. ApoB should be viewed as a complementary test rather than a substitute for standard lipid assessments, particularly when clinical evaluations and cholesterol readings do not align,” he adds.
“Indeed, elevated apoB levels alongside normal LDL cholesterol can alter the assessment of cardiovascular risk. Just because the total cholesterol level appears acceptable does not imply that there aren’t numerous cholesterol-carrying particles in circulation that could contribute to plaque accumulation in arteries.”
However, apoB testing is only one component of a comprehensive risk assessment. “Relying solely on apoB is insufficient for making treatment decisions. Physicians take into account a patient’s overall cardiovascular risk profile, including factors such as age, blood pressure, diabetes status, smoking habits, family history, and other risk-enhancing characteristics.”
If apoB levels are elevated in conjunction with other risk factors, healthcare providers may recommend initiating lifestyle changes sooner or intensifying lipid-lowering therapies. “For individuals with high apoB and additional risk factors, healthcare professionals may be more inclined to advocate for early lifestyle interventions or escalate lipid-lowering treatments, such as statins or other cholesterol-reducing medications.”
Ultimately, Dr. Talwar emphasizes that apoB facilitates a more individualized approach to risk management. “ApoB enhances risk evaluation and allows for a more personalized treatment strategy rather than merely replacing established risk assessment tools.”
While apoB testing is gradually becoming more accessible, it has yet to be integrated into routine preventive screenings in India. Dr. Talwar states, “Currently, apoB testing is available in numerous tertiary hospitals and private diagnostic facilities throughout India, but it has not yet become a standard component of lipid screening. The test generally costs more than a typical lipid profile, although prices have been steadily decreasing in urban areas.”
DISCLAIMER: This article is based on information from the public domain and/or the experts we consulted. Always seek the advice of your healthcare provider before beginning any new health regime.
